Resistance trends in Neisseria gonorrhoeae in southwestern Ohio.
BACKGROUND
Fluoroquinolone-resistant Neisseria gonorrhoeae strains originated in Eastern Asia in the 1980s; first appeared in United States during the early 1990 s in Hawaii, and subsequently spread to California and the continental US shortly after 2000. In 2007, the CDC recommended that fluoroquinolones should not be used as first-line therapy and recommended monitoring local resistance patterns to guide treatment recommendations. The Public Health-Dayton and Montgomery County STD Clinic tested N. gonorrhoeae isolates in 1996, 2001 and since 2006 to monitor susceptibility trends in the region.


METHODS
Cultures for N. gonorrhoeae were collected from male and female patients presenting to the Public Health-Dayton and Montgomery County STD Clinic. In 1996 and 2001, consecutive isolate were collected. Since 2006, 10 isolates were randomly selected per month. Susceptibility testing was performed using Etest strips. Susceptibility results were interpreted following the Clinical Laboratory Standards Institute guidelines.


RESULTS
In 1996, 102 isolates were tested; 85% were susceptible to ciprofloxacin (15% intermediate, 0% resistant) and 52% susceptible to tetracycline (39% intermediate, 9% resistant). In 2001, 106 isolates were tested; 100% were susceptible to ciprofloxacin and 76% susceptible to tetracycline (22% intermediate, 2% resistant). From 2006-2008, 286 isolates were tested; 98% were susceptible to ciprofloxacin (2% resistant), 60% susceptible to tetracycline (36% intermediate, 4% resistant) and 99% were susceptible to azithromycin.


CONCLUSIONS
Rates of ciprofloxacin resistance remain low in Montgomery County. Azithromycin is another potentially useful treatment; tetracycline is not acceptable for empirical therapy.
Herchline
Thomas E
TE
Department of Internal Medicine, Wright State University, Dayton, OH, USA. therchline@gmail.com
Inkrott
Bradley P
BP
D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D017963:Azithromycin / Q000494:pharmacology / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000494:pharmacology / Q000627:therapeutic use; D024881:Drug Resistance, Bacterial; D005260:Female; D006069:Gonorrhea / Q000188:drug therapy* / Q000453:epidemiology* / Q000382:microbiology; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D009344:Neisseria gonorrhoeae / Q000187:drug effects* / Q000302:isolation & purification; D009820:Ohio / Q000453:epidemiology; D013752:Tetracycline / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D002939:Ciprofloxacin; D017963:Azithromycin; D013752:Tetracycline